-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
With A 26% Price Drop For Viva Biotech Holdings (HKG:1873) You'll Still Get What You Pay For
With A 26% Price Drop For Viva Biotech Holdings (HKG:1873) You'll Still Get What You Pay For
To the annoyance of some shareholders, Viva Biotech Holdings (HKG:1873) shares are down a considerable 26% in the last month, which continues a horrid run for the company. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 77% loss during that time.
In spite of the heavy fall in price, given close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") below 8x, you may still consider Viva Biotech Holdings as a stock to avoid entirely with its 21x P/E ratio. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.
With earnings that are retreating more than the market's of late, Viva Biotech Holdings has been very sluggish. One possibility is that the P/E is high because investors think the company will turn things around completely and accelerate past most others in the market. If not, then existing shareholders may be very nervous about the viability of the share price.
Check out our latest analysis for Viva Biotech Holdings
SEHK:1873 Price Based on Past Earnings September 25th 2022 Want the full picture on analyst estimates for the company? Then our free report on Viva Biotech Holdings will help you uncover what's on the horizon.How Is Viva Biotech Holdings' Growth Trending?
There's an inherent assumption that a company should far outperform the market for P/E ratios like Viva Biotech Holdings' to be considered reasonable.
Retrospectively, the last year delivered a frustrating 53% decrease to the company's bottom line. As a result, earnings from three years ago have also fallen 22% overall. Accordingly, shareholders would have felt downbeat about the medium-term rates of earnings growth.
Looking ahead now, EPS is anticipated to climb by 98% per year during the coming three years according to the only analyst following the company. With the market only predicted to deliver 14% per year, the company is positioned for a stronger earnings result.
In light of this, it's understandable that Viva Biotech Holdings' P/E sits above the majority of other companies. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.
The Final Word
Even after such a strong price drop, Viva Biotech Holdings' P/E still exceeds the rest of the market significantly. Typically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.
As we suspected, our examination of Viva Biotech Holdings' analyst forecasts revealed that its superior earnings outlook is contributing to its high P/E. Right now shareholders are comfortable with the P/E as they are quite confident future earnings aren't under threat. Unless these conditions change, they will continue to provide strong support to the share price.
Before you take the next step, you should know about the 2 warning signs for Viva Biotech Holdings (1 is a bit unpleasant!) that we have uncovered.
Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with a strong growth track record, trading on a P/E below 20x.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
令一些股东恼火的是,Viva Biotech控股公司(HKG:1873)过去一个月,该公司股价大幅下跌26%,延续了可怕的涨势。最近的下跌为股东们灾难性的12个月画上了句号,在此期间,他们坐拥77%的损失。
尽管股价大幅下跌,但鉴于近一半的香港公司的市盈率(或“市盈率”)低于8倍,你可能仍会考虑将非凡生物科技控股公司作为一只股票,完全避免其21倍的市盈率。然而,仅仅从表面上看待市盈率是不明智的,因为可能会有一个解释,为什么它如此之高。
由于最近收益的回落幅度超过了市场,Viva Biotech Holdings一直非常低迷。一种可能性是,市盈率很高,因为投资者认为该公司将彻底扭转局面,加速超越市场上大多数其他公司。如果没有,那么现有股东可能会对股价的生存能力感到非常紧张。
查看我们对Viva Biotech Holdings的最新分析
联交所:1873基于过去收益的价格2022年9月25日想知道分析师对该公司的全面预期吗?那么我们的免费关于Viva Biotech Holdings的报告将帮助你发现地平线上的事情。Viva Biotech Holdings的增长趋势如何?
有一种固有的假设,即一家公司的市盈率应该远远超过市场,因为Viva Biotech Holdings的市盈率才是合理的。
回顾过去一年,该公司的利润令人沮丧地下降了53%。因此,三年前的整体收益也下降了22%。因此,股东们会对中期盈利增长率感到悲观。
根据跟踪该公司的唯一分析师的说法,展望未来三年,每股收益预计将以每年98%的速度攀升。由于市场预计每年只有14%的增长,该公司将迎来更强劲的收益结果。
有鉴于此,Viva Biotech Holdings的市盈率高于大多数其他公司是可以理解的。显然,股东们并不热衷于出售那些可能着眼于更繁荣未来的资产。
最后的结论
即使在如此强劲的价格下跌之后,Viva Biotech Holdings的市盈率仍然远远超过市场的其他部分。通常,在做出投资决策时,我们会告诫不要过度解读市盈率,尽管它可以充分揭示其他市场参与者对该公司的看法。
正如我们怀疑的那样,我们对Viva Biotech Holdings的分析师预测进行了审查,发现其优越的收益预期是导致其高市盈率的原因之一。目前,股东们对市盈率感到满意,因为他们非常有信心未来的收益不会受到威胁。除非这些条件改变,否则将继续为股价提供强有力的支撑。
在您采取下一步之前,您应该了解Viva Biotech Holdings的2个警告信号(1有点令人不快!)我们已经发现了。
当然了,通过观察几个优秀的候选人,你可能会发现这是一项非常棒的投资。所以让我们来看看这个免费业绩表现强劲、市盈率低于20倍的公司名单。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧